89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended March 31, 2021. “We are pleased to have received written guidance from the U.S. Food and Drug Administration (FDA) on our planned Phase 2b ENLIVEN trial design in non-alcoholic steatohepatitis (NASH),” said Rohan Palekar, Chief Executive Officer of 89bio. “We have a well-defined work plan ahead of us and are well-funded to reach multiple clinical and regulatory milestones, which we expect will continue to validate BIO89-100’s potential in both NASH and severe hypertriglyceridemia (SHTG).” Recent Highlights and Anticipated Milestones Received written guidance from the FDA on the Phase 2b ENLIVEN trial design, planned to initiate in 2Q21: ENLIVEN is a multi-center,
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.MarketBeat
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsGlobeNewswire
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ETNB
Earnings
- 11/8/23 - Beat
ETNB
Sec Filings
- 4/19/24 - Form ARS
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- ETNB's page on the SEC website